Stem cell therapy in Multiple Sclerosis: are we there yet?
Aristotle University of Thessaloniki · 21.12.2023
DOI: 10.26262/abj.v6i1.9902 ↗Kurz gefasst
Fachartikel in der Zeitschrift Aristotle University of Thessaloniki, erschienen am 21.12.2023. Verfasst von Kyrkou und 6 weiteren Autor:innen.
Abstract (Originalsprache)
Multiple sclerosis (MS) is characterized as a multifocal inflammatory disorder of the Central Nervous System (CNS) and is the most common cause of neurological disability in young adults worldwide. The etiopathogenesis of the disease is composed of gene and epigenetic mechanisms, viral infections, and other factors such as obesity and smoking. The pathophysiology is dominated by the presence of large confluent demyelinating lesions in the white matter of the CNS, and the diagnosis of the disease is the result of a combination of imaging and clinical features. As far as the available Disease Modifying Therapies (DMTs) are concerned, however, it is true that there are patients who do not have a reduction of inflammatory processes or are limited by the various side effects. Adding to the landscape of disease management is stem cell therapy, which involves transplanting patients with various types of stem cells, increasing the number of treatment options. The predominant stem cells that have been tested are mesenchymal stem cells, but other types of stem cells have also been studied, such as autologous hematopoietic stem cells, neural stem cells, human embryonic stem cells and induced pluripotent stem cells. In this review, Pubmed, ScienceDirect and Scopus databases were searched and the results of clinical trials from the last five years involving treatment with: a) umbilical cord mesenchymal stem cells, b) autologous hematopoietic stem cells, c) autologous -and non-autologous- mesenchymal stem cells and d) neural progenitor stem cells were summarized. Finally, clinical studies were collected: a) to evaluate NfL and CXCL13 levels in CSF after treatment with MSCs, b) to evaluate neurophysiological effects of TMS after treatment with aMSCs, c) to evaluate the safety and clinical efficacy of biomarkers of repeated intra-abdominal administration of MSC-NTF cells, and d) the results of the STEMS study.
Schlagwörter
Zitieren
APA
Kyrkou, Katerina, Manthou, Eleni, M., Meditskou, S., Theotokis, & Paschalis (2023). Stem cell therapy in Multiple Sclerosis: are we there yet?. Aristotle University of Thessaloniki. https://doi.org/10.26262/abj.v6i1.9902
Vancouver
Kyrkou, Katerina, Manthou, Eleni M, Meditskou S, Theotokis, et al. Stem cell therapy in Multiple Sclerosis: are we there yet?. Aristotle University of Thessaloniki. 2023. doi:10.26262/abj.v6i1.9902
BibTeX
@article{Kyrkou2023,
author = {Kyrkou and Katerina and Manthou and Eleni, Maria and Meditskou, Soultana and Theotokis and Paschalis},
title = {Stem cell therapy in Multiple Sclerosis: are we there yet?},
journal = {Aristotle University of Thessaloniki},
year = {2023},
doi = {10.26262/abj.v6i1.9902}
}
EUVIMED